The Life Sciences Report

"HLTH gives investors access to a market that's otherwise predominately privately held." (12/23/15) Nobilis Health Corp. - The Life Sciences Report Interview with Russell Stanley More >

"Durable survival was reported in AST's small Phase 2 trial in acute myeloid leukemia." (12/16/15) Asterias Biotherapeutics Inc. - The Life Sciences Report Interview with George Zavoico More >

"BOTA is well funded and has lots of clinical catalysts coming in 2016." (12/16/15) Biota Pharmaceuticals - The Life Sciences Report Interview with Jason Napodano More >

"RNN has three very interesting, early-stage anticancer drugs, and a sound development program." (12/16/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Jason Napodano More >

"BCT is early stage right now, but I really like the science." (12/16/15) BriaCell Therapeutics Corp. - The Life Sciences Report Interview with Jason Napodano More >

"SBOT is one of my favorites." (12/9/15) Stellar Biotechnologies Inc. - The Life Sciences Report Interview with Pierre Erwes More >

"ATHX's MultiStem is going to prove viable, and will change the paradigm for treating stroke." (12/2/15) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >

"MESO is one of the few companies that have the vision and know-how to commercialize regenerative medicine." (12/2/15) Mesoblast Ltd. - The Life Sciences Report Interview with Jason Kolbert More >

"I would encourage investors to look at STEM's data." (12/2/15) StemCells Inc. - The Life Sciences Report Interview with Jason Kolbert More >

"CYNA is now well funded, NASDAQ-listed and liquid; it isdefinitely among my better ideas as of today." (7/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >